Neurological Adverse Effects of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T-Cell Therapy

Immune checkpoint inhibitors (ICPIs) and chimeric antigen receptor (CAR) T-cell constitute recently approved novel therapies targeted to treat a wide number of malignancies. Both the treatments modulate the immune system and can cause a number of immune-related adverse events (irAEs), including poly...

Descripción completa

Detalles Bibliográficos
Autores principales: Khalid, Farhan, Gupta, Rajshree, Gor, Rajvi, Gor, Dairya, Singh, Vinit, Eltoukhy, Hussam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10181423/
https://www.ncbi.nlm.nih.gov/pubmed/37188042
http://dx.doi.org/10.14740/wjon1575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10181423/
https://www.ncbi.nlm.nih.gov/pubmed/37188042
http://dx.doi.org/10.14740/wjon1575

Ejemplares similares